Harmony (R3767-ONC-2011)

{ "short_title": "Harmony (R3767-ONC-2011)", "data_mode": "900", "data_mode_number": "000002303", "official_title": "A phase 3 trial of Fianlimab 8REgn3767, Anti-Lag-3) + Cemiplimab versus Pemprolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma", "accrual_state": "running", "therapeutic_value": "therapeutic", "therapieansatz_value": "palliativ", "therapieintervention_value": "not_applicable", "therapielinie_value": "first", "ctgov_number": null, "eudract_number": "2021-004453-23", "general_contact_email": "oncostudien.dermatologie@ukdd.de", "general_contact_phone": "+49 351-45819782", "hauptpruefer_dd_name": "Prof. Dr. med. Friedegund Meier", "description_laie_de": "Phase-III-Studie zu Fianlimab (REGN3767, Anti-LAG-3-Antik\u00f6rper) plus Cemiplimab versus Pembrolizumab bei Patienten mit zuvor unbehandeltem \r\nirresektablem lokal fortgeschrittenem oder metastasiertem Melanom.", "description_laie_en": null, "description_expert_de": null, "description_expert_en": "A phase 3 trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab versus Pembrolizumab in patients with repviously untreated unresectable locally advanced or metastatic melanoma.", "rechtsgrundlage_value": "AMG", "phase_amg_value": "III", "main_cat_id": 5, "sub_cat_id": 35 }